<DOC>
	<DOCNO>NCT00812292</DOCNO>
	<brief_summary>The purpose study evaluate much fast single , oral , daily 25 mg dose TMC278 absorb body administered solution , suspension , granule , tablet . In addition , effect formulation TMC278 evaluate patient fast fed state palatability ( drug taste ) formulation assess . Finally , safety tolerability formulation TMC278 assess throughout study .</brief_summary>
	<brief_title>TMC278-TiDP38-C145 : A Bioavailability Study Healthy Adult Volunteers Evaluate 3 Pediatric Formulations TMC278 ( Solution , Suspension , Granules ) Compared Adult Tablet Formulation</brief_title>
	<detailed_description>This open-label ( investigator volunteer know name assign study medication ) , randomize ( study medication assign chance ) cross-over study healthy adult compare rate extent absorption TMC278 administer single 25 mg dose 3 concept pediatric formulation ( solution [ 10 mg/mL ] , suspension [ 5 mg/mL ] , granule [ 2.5 mg/g ] ) , feed fasted condition , administer 25 mg TMC278 Phase III tablet formulation , fed condition , healthy adult assess effect food bioavailability TMC278 single 25 mg dose concept pediatric TMC278 formulation healthy adult . The palatability 3 concept formulation assess fasted state use questionnaire visual analog scale . The short-term safety tolerability TMC278 follow administration 3 single oral dos 25 mg , formulate one concept pediatric formulation ( feed fast condition ) Phase III tablet ( fed condition ) , healthy adult evaluate . TMC278 25 mg formulate solution , suspension , granule , tablet administer orally ( mouth ) . Each volunteer receive first day one treatment session one TMC278 25 mg tablet . On first day session receive single dose TMC278 25 mg formulate solution , suspension granule .</detailed_description>
	<mesh_term>Rilpivirine</mesh_term>
	<criteria>Nonsmoking smoke 10 cigarette , 2 cigar , 2 pipe per day least 3 month prior selection A Body Mass Index ( BMI , weight kg divide square height meter ) 18.0 30.0 kg/m2 , extremes include Informed Consent Form sign voluntarily first trialrelated activity Able comply protocol requirement Healthy basis medical evaluation reveals absence clinically relevant abnormality include physical examination , medical history , electrocardiogram , vital sign , result blood biochemistry hematology test urinalysis carry screening . A positive HIV1 2 test trial screen Female , except postmenopausal since two year , posthysterectomy posttubal ligation ( without reversal operation ) One risk factor QTc prolongation Currently active gastrointestinal , cardiovascular , neurologic , psychiatric , metabolic , renal , hepatic , respiratory , inflammatory infectious disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>TMC278</keyword>
	<keyword>TMC278-C145</keyword>
	<keyword>TMC278-TiDP38-C145</keyword>
	<keyword>concept pediatric formulation TMC278</keyword>
	<keyword>HIV Infections</keyword>
</DOC>